Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 (Q35266125)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 |
scientific article |
Statements
1 reference
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 (English)
1 reference
Bart Barlogie
1 reference
Sarah Waheed
1 reference
Elias Anaissie
1 reference
John D Shaughnessy
1 reference
Pingping Qu
1 reference
Saad Usmani
1 reference
Christoph J Heuck
1 reference
Qing Zhang
1 reference
Yiming Zhou
1 reference
Erming Tian
1 reference
Ichiro Hanamura
1 reference
Joshua Epstein
1 reference
Bijay Nair
1 reference
Owen Stephens
1 reference
Ryan Williams
1 reference
Yazan Alsayed
1 reference
John Crowley
1 reference
31 May 2011
1 reference
1 reference
118
1 reference
13
1 reference
3512-3524
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference